P093 INFLIXIMAB REINTRODUCTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE PREVIOUSLY TREATED WITH A 3-INFUSION INDUCTION REGIMEN IS NOT ASSOCIATED TO A HIGHER RATE OF IMMUNE-MEDIATED ADVERSE EFFECTS | Zendy

AI Assistant Blog Pricing

P093 INFLIXIMAB REINTRODUCTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE PREVIOUSLY TREATED WITH A 3-INFUSION INDUCTION REGIMEN IS NOT ASSOCIATED TO A HIGHER RATE OF IMMUNE-MEDIATED ADVERSE EFFECTS

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.